{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:03:16Z","timestamp":1784808196186,"version":"3.55.0"},"reference-count":34,"publisher":"Jaypee Brothers Medical Publishing","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.59556\/japi.74.1507","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:31:02Z","timestamp":1781602262000},"page":"94-96","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon Agonist Therapies and Vision Loss: Balancing Promise with Prudence in India"],"prefix":"10.59556","volume":"74","author":[{"given":"Abhyuday","family":"Saxena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(13):","key":"key20260723112531_B1","doi-asserted-by":"crossref","first-page":"10449.","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials.","volume":"24","author":"Popoviciu","year":"2023;","journal-title":"Int J Mol Sci"},{"key":"key20260723112531_B2","doi-asserted-by":"crossref","first-page":"102782.","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.","volume":"75:","author":"Alfaris","year":"2024;","journal-title":"eClinicalMedicine"},{"key":"key20260723112531_B3","unstructured":"Grand View Research. (2026). GLP-1 receptor agonist market size and share report, 2030. [online] Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/glp-1-receptor-agonist-market [Last accessed May, 2026]."},{"key":"key20260723112531_B4","unstructured":"American Optometric Association-Evidence-based Optometry Committee. (2025). Clinical report: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ocular health: guidance for optometric practice. [online] Available from: https:\/\/www.aoa.org\/AOA\/Documents\/Practice%20Management\/Clinical%20Guidelines\/AOA%20GLP-1_EBO_clinical-report.pdf [Last accessed May, 2026]."},{"issue":"(7):","key":"key20260723112531_B5","doi-asserted-by":"crossref","first-page":"474\u2013","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).","volume":"11","author":"Anjana","year":"2023;","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key20260723112531_B6","unstructured":"Industry report 2030. (2026). India GLP-1 receptor agonist market. [online] Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/india-glp-1-receptor-agonist-market-report [Last accessed May, 2026]."},{"key":"key20260723112531_B7","unstructured":"Market.us. (2026) GLP-1 receptor agonist market. [online] Available from: https:\/\/market.us\/report\/glp-1-receptor-agonist-market\/ [Last accessed May, 2026]."},{"key":"key20260723112531_B8","unstructured":"Research and Markets. (2026). GLP-1 receptor agonist market size, share, and forecast to 2030. [online] Available from: https:\/\/www.researchandmarkets.com\/reports\/5533031\/glp-1-receptor-agonist-market-global-forecast [Last accessed May, 2026]."},{"issue":"(3):","key":"key20260723112531_B9","doi-asserted-by":"crossref","first-page":"287\u2013","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.","volume":"24","author":"Luo","year":"2025;","journal-title":"Expert Opin Drug Saf"},{"issue":"(1):","key":"key20260723112531_B10","first-page":"80\u2013","article-title":"Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database.","volume":"88","author":"Zhou","year":"2025;","journal-title":"Endocrine"},{"key":"key20260723112531_B11","doi-asserted-by":"crossref","first-page":"148\u2013","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries.","volume":"277:","author":"Lakhani","year":"2025;","journal-title":"Am J Ophthalmol"},{"issue":"(6):","key":"key20260723112531_B12","doi-asserted-by":"crossref","first-page":"1071\u2013","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials.","volume":"68","author":"Kapoor","year":"2023;","journal-title":"Surv Ophthalmol"},{"issue":"(1):","key":"key20260723112531_B13","first-page":"290\u2013","article-title":"HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression.","volume":"44","author":"Bethel","year":"2020;","journal-title":"Diabetes Care"},{"issue":"(4):","key":"key20260723112531_B14","doi-asserted-by":"crossref","first-page":"390\u2013","DOI":"10.1080\/09286586.2024.2399764","article-title":"Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy.","volume":"32","author":"Tauqeer","year":"2025;","journal-title":"Ophthalmic Epidemiol"},{"issue":"(4):","key":"key20260723112531_B15","doi-asserted-by":"crossref","first-page":"704\u2013","DOI":"10.1016\/j.survophthal.2025.01.010","article-title":"An update on ocular effects of antidiabetic medications.","volume":"70","author":"Sadeghi","year":"2025;","journal-title":"Surv Ophthalmol"},{"issue":"(6):","key":"key20260723112531_B16","doi-asserted-by":"crossref","first-page":"3094\u2013","DOI":"10.1111\/dom.16316","article-title":"Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: a Danish\u2013Norwegian cohort study.","volume":"27","author":"Simonsen","year":"2025;","journal-title":"Diabetes Obes Metab"},{"issue":"(8):","key":"key20260723112531_B17","doi-asserted-by":"crossref","first-page":"e2526327.","DOI":"10.1001\/jamanetworkopen.2025.26327","article-title":"Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes.","volume":"8","author":"Wang","year":"2025;","journal-title":"JAMA Netw Open"},{"issue":"(8):","key":"key20260723112531_B18","doi-asserted-by":"crossref","first-page":"732\u2013","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.","volume":"142","author":"Hathaway","year":"2024;","journal-title":"JAMA Ophthalmol"},{"key":"key20260723112531_B19","first-page":"991\u2013","article-title":"Nonarteritic anterior ischemic optic neuropathy in an otherwise healthy young adult patient treated with liraglutide and semaglutide for weight loss: a cautionary tale.","volume":"18:","author":"Lixi","year":"2025;","journal-title":"Int Med Case Rep J"},{"issue":"(2):","key":"key20260723112531_B20","doi-asserted-by":"crossref","first-page":"1005\u2013","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1(GLP1) receptor agonists and risk for ischemic optic neuropathy: a meta-analysis of randomised controlled trials.","volume":"27","author":"Silverii","year":"2025;","journal-title":"Diabetes Obes Metab"},{"key":"key20260723112531_B21","unstructured":"World Health Organization. (2025). The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). [online] Available from: https:\/\/www.who.int\/news\/item\/27-06-2025-27-06-2025-semaglutide-medicines-naion [Last accessed May, 2026]."},{"key":"key20260723112531_B22","unstructured":"European Medicines Agency (EMA). (2025). PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus, and Wegovy. [online] Available from: https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy [Last accessed May, 2026]."},{"issue":"(8):","key":"key20260723112531_B23","doi-asserted-by":"crossref","first-page":"11\u2013","DOI":"10.59556\/japi.72.0621","article-title":"Nonarteritic anterior ischemic optic neuropathy and semaglutide: what is this all about?","volume":"72","author":"Singh","year":"2024;","journal-title":"J Assoc Physicians India"},{"issue":"(3):","key":"key20260723112531_B24","doi-asserted-by":"crossref","first-page":"215\u2013","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide.","volume":"143","author":"Katz","year":"2025;","journal-title":"JAMA Ophthalmol"},{"key":"key20260723112531_B25","unstructured":"Patorno E, Desai R, Anand P, et al. (2025). Risk of non-arteritic anterior ischemic optic neuropathy (NAION) following GLP-1 receptor agonist use in patients with type 2 diabetes mellitus: A HARPER study protocol. [online] Available from: https:\/\/sentinelinitiative.org\/sites\/default\/files\/documents\/Risk-of-NAION-Following-GLP-1-Receptor-Agonist-Use-in-Patients-with-Type-2-Diabetes-Mellitus_Protocol_Public_Comment_v1.0.pdf. [Last accessed May, 2026]."},{"key":"key20260723112531_B26","article-title":"Does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy? A systematic review and meta-analysis of emerging evidence.","author":"Chen","year":"2025;","journal-title":"Asia-Pac J Ophthalmol"},{"key":"key20260723112531_B27","doi-asserted-by":"crossref","first-page":"5.","DOI":"10.21037\/aes-24-38","article-title":"Re-examining the putative association between GLP-1 receptor agonists and nonarteritic anterior ischemic optic neuropathy.","volume":"10:","author":"Poonja","year":"2025;","journal-title":"Ann Eye Sci"},{"key":"key20260723112531_B28","first-page":"12.","article-title":"The burgeoning cardiovascular disease epidemic in Indians \u2013 perspectives on contextual factors and potential solutions.","author":"Kalra","year":"2023;","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"(11):","key":"key20260723112531_B29","first-page":"e73786.","article-title":"The rising burden of cardiovascular disease and thrombosis in India: an epidemiological review.","volume":"16","author":"Loitongbam","year":"2024;","journal-title":"Cureus"},{"issue":"(4):","key":"key20260723112531_B30","first-page":"e37467.","article-title":"Risk factors associated with hypertension in young adults: a systematic review.","volume":"15","author":"Meher","year":"2023;","journal-title":"Cureus"},{"issue":"(Suppl 1):","key":"key20260723112531_B31","doi-asserted-by":"crossref","first-page":"S101\u2013","DOI":"10.1016\/j.ihj.2023.11.265","article-title":"Managing dyslipidaemia in young adults.","volume":"76","author":"Dalal","year":"2024;","journal-title":"Indian Heart J"},{"issue":"(17):","key":"key20260723112531_B32","doi-asserted-by":"crossref","first-page":"3389\u2013","DOI":"10.1038\/s41433-024-03266-z","article-title":"Patient perspectives on accessing eye-related healthcare from rural communities.","volume":"38","author":"Rao","year":"2024;","journal-title":"Eye"},{"issue":"(2):","key":"key20260723112531_B33","doi-asserted-by":"crossref","first-page":"330\u2013","DOI":"10.4103\/IJO.IJO_105_23","article-title":"Rural development through eye care: a new dimension of possibilities.","volume":"71","author":"Jain","year":"2023;","journal-title":"Indian J Ophthalmol"},{"key":"key20260723112531_B34","doi-asserted-by":"crossref","first-page":"q1605.","DOI":"10.1136\/bmj.q1605","article-title":"India: doctors report surge in use of off label GLP-1 agonists among rich.","volume":"386:","author":"Lal","year":"2024;","journal-title":"BMJ"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:25:42Z","timestamp":1784805942000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-6-94"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.59556\/japi.74.1507"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1507","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}